文献速递头颈部肿瘤放疗放疗物理与技术

68Ga-FAPI-PET/CT 改善腺样囊性癌分期与放疗计划

68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas - Imaging analysis and histological validation.
PubMed 文献 · Radiother Oncol · 2021-05-01

该研究纳入 12 例腺样囊性癌(ACC)患者(7 例初治、5 例复发),对比 68Ga-FAPI-PET/CT 与增强 CT/MRI 的分期和放疗计划价值。结果显示 68Ga-FAPI-PET/CT 使 2/12 例升期、3 例检出额外转移,共 42% 患者分期改变,并提高靶区勾画准确性。

要点

  • 68Ga-FAPI-PET/CT 在全部 ACC 中呈 tracer 摄取升高,免疫组化证实肿瘤内 FAP 表达 CAFs。
  • 相比常规分期,68Ga-FAPI-PET/CT 使 42% 患者分期改变(2/12 升期,3 例检出额外转移)。
  • 68Ga-FAPI-PET/CT 较 CT 和 MRI 提高放疗靶区勾画准确性。

核心结论

  • 68Ga-FAPI-PET/CT 是 ACC 有前景的成像手段,较常规 CT 和 MRI 提高分期检查与放疗计划靶区的准确性。

研究设计与样本

  • 研究纳入 12 例 ACC 患者(7 例初治、5 例复发),行 68Ga-FAPI-PET/CT 并与增强 CT 和增强 MRI 对比分期和放疗计划。
  • PET 扫描在注射 150-250 MBq 68Ga 标记 FAPI 示踪剂后 10、60、180 分钟采集,以 60% 最大等轮廓获取 SUVmax 和 SUVmean。
  • 对 13 例(3 例有、10 例无 68Ga-FAPI-PET/CT)行 FAP 和 α-SMA 免疫组化。

主要发现

  • 全部 ACC 均观察到示踪剂摄取升高,免疫组化显示肿瘤内 FAP 表达 CAFs。
  • 相比常规分期,68Ga-FAPI-PET/CT 使 2/12 例升期并检出 3 例额外转移,共 42% 患者分期改变。
  • 68Ga-FAPI-PET/CT 较 CT 和 MRI 提高放疗靶区勾画准确性。

关键数值与推荐

  • PET 扫描在注射 150-250 MBq 68Ga 标记 FAPI 示踪剂后 10、60、180 分钟采集。
  • SUVmax 和 SUVmean 采用 60% 最大等轮廓获取。
  • 12 例中 2 例升期、3 例检出额外转移,共 42% 患者分期改变。

临床怎么用

  • 对 ACC 患者可考虑 68Ga-FAPI-PET/CT 辅助分期,以发现常规 CT/MRI 未显示的转移并调整分期。
  • 放疗计划中可参考 68Ga-FAPI-PET/CT 提高靶区勾画准确性。

局限性

  • 样本量小(12 例 ACC 患者),需更大研究验证。
  • 免疫组化仅 13 例,其中 3 例有 68Ga-FAPI-PET/CT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adenoid cystic carcinomas (ACCs) are rare epithelial tumors mostly situated in the head and neck region and characterized by infiltrative growth. The tumor stroma of ACCs includes cancer-associated fibroblasts (CAFs) expressing Fibroblast Activation Protein (FAP), a new target for positron emission tomography (PET) imaging. Here we describe the value of PET/ computed tomography (PET/CT) imaging using 68Ga-labelled FAP-Inhibitors (68Ga-FAPI-PET/CT) and their clinical potential for staging and radiotherapy planning in 12 ACC patients (7 primary, 5 recurrent). PATIENTS AND METHODS: Patients underwent contrast enhanced staging CT (ceCT) and magnetic resonance imaging (ceMRI) before 68Ga-FAPI - PET/CT. PET-scans were acquired 10, 60 and 180 minutes after administration of 150-250 MBq of 68Ga-labelled FAPI tracers. SUVmax and SUVmean values of ACCs and healthy organs were obtained using a 60% of maximum iso-contour. FAP and alpha smooth muscle actin (α-SMA) immunohistochemistry was performed in 13 cases (3 with and 10 without 68Ga FAPI-PET/CT). Staging and radiotherapy planning based on 68Ga-FAPI-PET/CT versus ceCT/MRI alone were compared. RESULTS: We observed elevated tracer uptake in all ACCs. Immunohistochemistry showed FAP-expressing CAFs in the tumor. Compared to conventional staging, 68Ga-FAPI-PET/CT led to upstaging in 2/12 patients and to detection of additional metastases in 3 patients, thus in total 42% of patients had their staging altered. Moreover, 68Ga-FAPI PET improved the accuracy of target volume delineation for radiotherapy, as compared to CT and MRI. CONCLUSION: 68Ga-FAPI-PET/CT is a promising imaging modality for ACC, increasing the accuracy of staging exams and radiotherapy planning volumes, as compared conventional to CT and MRI.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Röhrich M, Syed M, Liew DP, et al. 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas - Imaging analysis and histological validation. Radiother Oncol. 2021. PMID: 33940087. doi:10.1016/j.radonc.2021.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。